Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
INDERIDE LA 120/50 is a fixed-dose combination of propranolol hydrochloride (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic) formulated as an extended-release capsule. It is indicated for hypertension management in patients who require dual antihypertensive therapy. The combination works by reducing cardiac output and peripheral vascular resistance while promoting sodium and fluid excretion.
Product is in late-stage lifecycle with moderate competitive pressure; commercial teams are typically managing decline and optimizing profitability rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on INDERIDE LA offers limited career growth opportunity given the product's LOE-approaching status and minimal linked job openings (0 positions). This role is best suited for professionals seeking stability in a mature franchise or transition experience before moving to growth-stage products.
Worked on INDERIDE LA 120/50 at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.